Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cytokinetics, Incorporated (CYTK) had Consolidated Net Income/Loss of $-306.18M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.94M |
|
$-306.18M |
|
-- |
|
$1.94M |
|
$168.69M |
|
$-166.75M |
|
$-139.42M |
|
$-306.18M |
|
$-306.18M |
|
$-306.18M |
|
$-306.18M |
|
|
Consolidated Net Income/Loss |
$-306.18M |
$-306.18M |
|
$-166.75M |
|
$-164.08M |
|
119.98M |
|
119.98M |
|
$-2.55 |
|
$-2.55 |
|
| Balance Sheet Financials | |
$977.35M |
|
$76.00M |
|
$459.21M |
|
$1.44B |
|
$142.14M |
|
$1.05B |
|
$1.82B |
|
$1.96B |
|
$-521.12M |
|
$-521.12M |
|
$-521.12M |
|
122.12M |
|
| Cash Flow Statement Financials | |
$-367.36M |
|
$87.86M |
|
$413.75M |
|
$95.23M |
|
$228.58M |
|
$133.35M |
|
$81.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.88 |
|
-- |
|
-- |
|
1.99 |
|
-2.08 |
|
100.00% |
|
-8613.38% |
|
-8613.38% |
|
-- |
|
-15814.98% |
|
-15814.98% |
|
$-386.52M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
1.07 |
|
84.05 |
|
58.75% |
|
58.75% |
|
-21.31% |
|
-58.08% |
|
$-4.27 |
|
$-3.22 |
|
$-3.06 |
|